Showing results (71-80 of 92) with videos related to
Sort By:
Pageof 10
JTO Clinical and Research Reports|June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLCAlexander Drilon, Chao-Hua Chiu, Yun Fan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or LeptomeningesLaura Q M Chow, Fabrice Barlesi, Erin M Bertino, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLCKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.Lung Cancer (Amsterdam, Netherlands)|July 27, 2014
Latent TB infection in newly diagnosed lung cancer patients - A multicenter prospective observational studyWen-Chien Fan, Wen-Ying Ting, Ming-Che Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerRafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2025
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief ReportAlexander I Spira, Luis Paz-Ares, Ji-Youn Han, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2025
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN StudyYi-Long Wu, Hye Ryun Kim, Ross A Soo, et al.JTO Clinical and Research Reports|May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced <i>ALK</i>-Positive NSCLCQing Zhou, Ross A Soo, Gee-Chen Chang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.Pageof 10